China’s biotech industry is going through a renaissance. The country is laser-focused on becoming a global leader in oncology, and it’s plowing resources into supporting its domestic drugmakers.

7investing advisor Simon Erickson’s Top Stock for July is completely off the radar of other investors, but it won’t be that way for long. The company is driving innovative new therapies to market in an accelerated timeframe. And an important event that just took place in November could result in significant future profits for investors.

[vc_cta h2=”Empowering you to invest in your future!” h4=”Subscribe to 7investing to get direct access to Simon’s report.”][su_list icon=”icon: line-chart” icon_color=”#84c136″]

[/su_list]

Sign up today!

[/vc_cta]

Transcript

Hi, I’m 7investing lead advisor Simon Erickson. Here at 7investing, our team finds our 7 favorite stock market opportunities every month and we provide them to subscribers for just $17. Earlier today, our team just published our newest reports of our top stocks for July.

My top idea this month is a company that’s completely off the radar of other investors. I’ve yet to see it mentioned in any other investment newsletter, and it’s not yet attracting any attention from Wall Street’s analysts.

That’s a huge opportunity for us, to get in early to this innovative healthcare leader early, before others take note of its growing track record of success.

Biotechnology and oncology are already developed in many places around the world. The United States and Europe already spend $100 billion per year on cancer-fighting drugs ever year, already have state-of-the-art facilities, and already have a mature medical insurance reimbursement system to help pick up the tab. 

This is a very important field, which is very truly saving peoples’ lives.

China is still far behind the US, but it’s going “all-in” on creating its very own War on Cancer. It has more oncology patients than in Europe and the United States combined, it’s committied billions of dollars to support innovative research, and its regulators are demanding quality from new drugmakers.

That creates a huge opportunity for the company I’m recommending this month, who is creating a new wave of incredibly effective medicines. 

It’s recently won regulatory approval — both within China, but also within the United States — giving it commercial access to sell its products in the world’s most developed and fastest-growing markets! 

My Top Stock for July is a company that I think belongs on your investing radar. It’s a company that’s playing a crucial role in China’s fast-growing biotechnology market. 

To see the name of the company that I’m recommending, simply click on the link at the end of this video to start your 7investing subscription and get direct access to my report. 

We’re here to empower you to invest in your future. We are 7investing!